Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Autek China Inc. (300595.SZ)
CNY11.16
+0.34 (+3.14%)
CN SHZ Healthcare Medical - Instruments & Supplies
Address
No. 4899 Wangjiang West Road 230088
Hefei, CN
Hefei, CN
CEO
Yuequn Tao
Website
orthok.cn
IPO
2017-01-18
ISIN CNE100002MR0
Description
Autek China Inc. focuses its operations on the entire process from conceptualization and development to the manufacturing and distribution of products related to ocular health and visual care. The company's offerings prominently feature specialized ophthalmic medical devices, including orthokeratology lenses, which are utilized for improving eyesight and managing the progression of short-sightedness. This enterprise was founded in 2001 and is primarily based in Hefei, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY11.16
+0.34 (+3.14%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11M
Beta
0.55
Float Shares
601.90M
Free Float %
67.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.51% | -2.74% | -16.23% | -24.22% | -23.16% | -17.77% | -20.37% | -57.06% | -88.06% | +331.43% | +331.43% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
11.16
DCF (Unlevered)
14.52
+30.1%
DCF (Levered)
21.59
+93.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
9.24
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%+2.0% Q1'26: -3.9% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-15.6% Q1'26: -10.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+27.1% Q1'26: +33.4% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+33.7% ★ Q1'26: +34.7% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+20.9% ★ Q1'26: +16.3% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.2% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.49× ★ Q1'26: 0.35× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
311.63M
est: 303.00M (+2.8%)
|
458.42M
est: 462.00M (-0.8%)
|
646.90M
est: 623.95M (+3.7%)
|
870.66M
est: 882.50M (-1.3%)
|
1.30B
est: 1.26B (+2.7%)
|
1.53B
est: 1.70B (-10.5%)
|
1.74B
est: 1.84B (-5.6%)
|
1.81B
est: 1.86B (-2.4%)
|
1.85B
est: 1.79B (+3.2%)
|
1.97B
1.88B – 2.09B
+9.7% YoY
|
2.10B
1.91B – 2.39B
+6.9% YoY
|
| EBITDA |
169.60M
est: 141.80M (+19.6%)
|
222.94M
est: 216.22M (+3.1%)
|
305.40M
est: 292.01M (+4.6%)
|
444.70M
est: 413.01M (+7.7%)
|
634.37M
est: 589.93M (+7.5%)
|
733.22M
est: 797.47M (-8.1%)
|
784.57M
est: 797.18M (-1.6%)
|
738.24M
est: 805.06M (-8.3%)
|
622.97M
est: 776.76M (-19.8%)
|
852.31M
816.14M – 906.22M
+9.7% YoY
|
911.36M
828.11M – 1.03B
+6.9% YoY
|
| EBIT |
164.94M
est: 134.25M (+22.9%)
|
214.41M
est: 204.70M (+4.7%)
|
288.64M
est: 276.45M (+4.4%)
|
417.90M
est: 391.01M (+6.9%)
|
603.53M
est: 558.50M (+8.1%)
|
697.25M
est: 754.98M (-7.6%)
|
746.69M
est: 762.63M (-2.1%)
|
693.48M
est: 770.17M (-10.0%)
|
622.97M
est: 743.10M (-16.2%)
|
815.37M
780.77M – 866.94M
+9.7% YoY
|
871.86M
792.22M – 989.21M
+6.9% YoY
|
| Net Income |
150.86M
est: 152.87M (-1.3%)
|
216.24M
est: 227.73M (-5.0%)
|
306.89M
est: 451.76M (-32.1%)
|
433.32M
est: 446.20M (-2.9%)
|
554.74M
est: 620.45M (-10.6%)
|
623.85M
est: 689.16M (-9.5%)
|
666.60M
est: 680.33M (-2.0%)
|
572.23M
est: 630.42M (-9.2%)
|
479.52M
est: 536.41M (-10.6%)
|
507.19M
499.27M – 514.15M
-5.4% YoY
|
555.94M
496.30M – 615.58M
+9.6% YoY
|
| SGA |
54.18M
est: 80.67M (-32.8%)
|
104.34M
est: 123.01M (-15.2%)
|
157.98M
est: 166.13M (-4.9%)
|
187.94M
est: 234.96M (-20.0%)
|
336.31M
est: 335.62M (+0.2%)
|
415.06M
est: 453.69M (-8.5%)
|
480.87M
est: 517.90M (-7.1%)
|
556.37M
est: 523.02M (+6.4%)
|
539.73M
est: 504.63M (+7.0%)
|
553.71M
530.21M – 588.73M
+9.7% YoY
|
592.07M
537.99M – 671.76M
+6.9% YoY
|
| EPS |
0.18
est: 0.17 (+6.2%)
|
0.26
est: 0.25 (+2.4%)
|
0.36
est: 0.50 (-28.5%)
|
0.51
est: 0.50 (+3.3%)
|
0.65
est: 0.69 (-5.5%)
|
0.72
est: 0.77 (-6.8%)
|
0.74
est: 0.76 (-2.4%)
|
0.64
est: 0.69 (-7.2%)
|
0.54
est: 0.59 (-8.0%)
|
0.57
0.56 – 0.57
-3.5% YoY
|
0.61
0.55 – 0.69
+7.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
656.39M
OE per share TTM
0.73
Owner's Yield
6.07%
Maintenance CapEx ratio
17.61%
Maint CapEx / Avg PPE
35.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 30 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 5.9K | 0.15% |
| 2 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 132.1K | 0.19% |
| 3 | State Street SPDR S&P China ETF GXC | 0.01% | 25.5K | 0.59% |
| 4 | Franklin FTSE China ETF FLCH | 0.00% | 10.4K | 0.19% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 236.7K | 0.39% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 97.7K | 0.29% |
| 7 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 20.3K | 0.46% |
| 8 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 127.4K | 0.06% |
| 9 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 27.9K | 0.26% |
| 10 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 12.4K | 0.48% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
174.0K
Shares Outstanding
895.29M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guoxin Dong | Deputy General Manager | — | male |
| Lizhi Wei | Chief Financial Officer & Non-Independent Director | — | male |
| Xianmei Shi | Deputy GM, Secretary, Operations Director & Non-Independent Director | — | female |
| Yongzhan Xiao | Deputy General Manager | — | male |
| Yuequn Tao | GM & Chairman | — | male |
| Zhe Zhu | Deputy General Manager | — | male |
| Zhiying Fu | Deputy General Manager | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300595.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
